NEW YORK (GenomeWeb News) – Biodesix today announced the closing of a $12 million extension of its Series D financing round.

The funds will support commercialization of its VeriStrat blood-based test for non-small cell lung cancer, as well as clinical validation studies, product development, and ongoing collaborations with biotechnology and pharmaceutical companies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.